Joost Vermaat

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (13)

Tom van Meerten

University of Groningen

NETHERLANDS

View details

Josée M. Zijlstra

NETHERLANDS

View details

Erik van Werkhoven

Erasmus University Rotterdam

NETHERLANDS

View details

F. J. Sherida H. Woei‐A‐Jin

BELGIUM

View details

Thomas Tousseyn

Professor Dr. at KU Leuven

KU Leuven

BELGIUM

View details

Pieternella J. Lugtenburg

University Medical Center

NETHERLANDS

View details

Johanna Bult

University Medical Center Groningen

NETHERLANDS

View details

Maarten Vermeer

Prof dr

Leiden University Medical Center

NETHERLANDS

View details

Marcel Nijland

University of Groningen

NETHERLANDS

View details

Arjan Diepstra

University Medical Center Groningen

NETHERLANDS

View details

Olivier Casasnovas

FRANCE

View details

Anke Van den Berg

University of Groningen

NETHERLANDS

View details

Monique C. Minnema

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Joost Vermaat

Research Interests

Explore related searches

Contact this professor

Articles (10)

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome

Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Collaborators (13)

Tom van Meerten

Josée M. Zijlstra

Erik van Werkhoven

F. J. Sherida H. Woei‐A‐Jin

Thomas Tousseyn

Pieternella J. Lugtenburg

Johanna Bult

Maarten Vermeer

Marcel Nijland

Arjan Diepstra

Olivier Casasnovas

Anke Van den Berg

Monique C. Minnema

Make your next move.

Joost Vermaat

Research Interests

Explore related searches

Contact this professor

Articles (10)

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren&rsquo;s Syndrome

Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Collaborators (13)

Tom van Meerten

Josée M. Zijlstra

Erik van Werkhoven

F. J. Sherida H. Woei‐A‐Jin

Thomas Tousseyn

Pieternella J. Lugtenburg

Johanna Bult

Maarten Vermeer

Marcel Nijland

Arjan Diepstra

Olivier Casasnovas

Anke Van den Berg

Monique C. Minnema

Make your next move.

Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome